Skip to content
Screener

Bausch + Lomb BLCO Vision Care — Operating Income (Loss)

Other segment segments

Pharmaceuticals
$89M+141%
Surgical
$17M+750%

Similar metrics at other companies

Becton, Dickinson and Company logo
BDXConnected Care — Operating Income (Loss)
$347M-1.7%
Bright Horizons Family Solutions logo
BFAMBack-up care — Operating Income (Loss)
$50.28M+22.9%
ResMed logo
RMDResidential Care Software — Operating Income (Loss)
$58.24M+9.5%
Huntington Ingalls Industries logo
HIIMission Technologies — Operating Income (Loss)
$55M+52.8%
Fluor logo
FLRMission Solutions — Operating Income (Loss)
$44M+25.7%
USANA Health Sciences logo
USNACore Nutritional — Operating Income (Loss)
$18.25M+7.8%

Other financials

Income statement

See full
Revenue$1.4B+9.1%
Operating income$83.0M+855%
Net income-$14.0M+77.4%
EPS (diluted)-$0.04+77.8%

Balance sheet

See full
Cash & equivalents$378.0M+39.0%
Total debt$5.1B+2.4%
Total equity$6.4B-1.0%
Total assets$13.9B+0.2%

Cash flow

See full
Operating cash flow$153.0M+337%
CapEx$71.0M-20.2%
Free cash flow$82.0M+252%

Valuation

See full
Market cap$5.84B+17.0%
Enterprise value$10.54B+8.9%
P/S1.1×+0.1×

Profitability

See full
Operating margin6.1%+5.3pp
Net margin-3.2%-1.0pp
FCF margin-3.4%0.0pp

Returns & leverage

See full
Return on equity-2.7%-0.7pp
Debt / equity0.8×0.0×
Current ratio1.5×0.0×

Where this comes from

Reported directly by Bausch + Lomb in its filing.

Tagged under the XBRL concept us-gaap:OperatingIncomeLoss.

The source filing: Bausch + Lomb’s 10-Q, filed July 29, 2026.

Filed
Jul 29, 2026, 4:17 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001860742-26-000088
(in millions)Vision Care / Three Months Ended June 30, 2026Vision Care / Three Months Ended June 30, 2025Pharmaceuticals / Three Months Ended June 30, 2026Pharmaceuticals / Three Months Ended June 30, 2025Surgical / Three Months Ended June 30, 2026Surgical / Three Months Ended June 30, 2025Total / Three Months Ended June 30, 2026Total / Three Months Ended June 30, 2025
Cost of other revenues2
Selling, general and administrative2472431491548073
Research and development171127121212
Segment Profit$229$209$89$37$17$2335248
Corporate(170)(170)
Amortization of intangible assets(57)(67)
Other expense, net(25)(22)
Operating income (loss)83(11)

Item 1. Condensed Consolidated Financial Statements (unaudited)

FAQ

What is Bausch + Lomb's vision care — operating income (loss)?
Bausch + Lomb (BLCO) reported vision care — operating income (loss) of $229M in Q2 2026.
How has Bausch + Lomb's vision care — operating income (loss) changed year-over-year?
Bausch + Lomb's vision care — operating income (loss) increased by 9.6% year-over-year, from $209M to $229M.
What is the long-term trend for Bausch + Lomb's vision care — operating income (loss)?
Over 4 years (2021 to 2025), Bausch + Lomb's vision care — operating income (loss) has grown at a 10.2% compound annual growth rate (CAGR), from $576M to $849M.
What does vision care — operating income (loss) mean?
Calculated as the segment's total revenue minus its direct operating expenses, including R&D and SG&A. This metric provides a clear view of the core profitability of the Vision Care business before interest and taxes. It is the primary benchmark for assessing the operational efficiency and margin performance of the segment.

Ask your AI about Bausch + Lomb's vision care — operating income (loss).

Connect your AI assistant and compare segments, right in your chat.

Connect your AI
Harbor at dusk
Claude